192 related articles for article (PubMed ID: 21040141)
21. Successful treatment of chronic antibody-mediated rejection with IVIG and rituximab in pediatric renal transplant recipients.
Billing H; Rieger S; Ovens J; Süsal C; Melk A; Waldherr R; Opelz G; Tönshoff B
Transplantation; 2008 Nov; 86(9):1214-21. PubMed ID: 19005402
[TBL] [Abstract][Full Text] [Related]
22. Current treatments of chronic immune-mediated demyelinating polyneuropathies.
Brannagan TH
Muscle Nerve; 2009 May; 39(5):563-78. PubMed ID: 19301378
[TBL] [Abstract][Full Text] [Related]
23. A randomised controlled trial of intravenous immunoglobulin in IgM paraprotein associated demyelinating neuropathy.
Comi G; Roveri L; Swan A; Willison H; Bojar M; Illa I; Karageorgiou C; Nobile-Orazio E; van den Bergh P; Swan T; Hughes R; Aubry J; Baumann N; Hadden R; Lunn M; Knapp M; Léger JM; Bouche P; Mazanec R; Meucci N; van der Meché F; Toyka K;
J Neurol; 2002 Oct; 249(10):1370-7. PubMed ID: 12382151
[TBL] [Abstract][Full Text] [Related]
24. Intravenous immunoglobulin in primary and secondary chronic progressive multiple sclerosis: a randomized placebo controlled multicentre study.
Pöhlau D; Przuntek H; Sailer M; Bethke F; Koehler J; König N; Heesen C; Späth P; Andresen I
Mult Scler; 2007 Nov; 13(9):1107-17. PubMed ID: 17623736
[TBL] [Abstract][Full Text] [Related]
25. Diagnosis and treatment of chronic acquired demyelinating polyneuropathies.
Latov N
Nat Rev Neurol; 2014 Aug; 10(8):435-46. PubMed ID: 24980070
[TBL] [Abstract][Full Text] [Related]
26. Predictors of response to rituximab in patients with neuropathy and anti-myelin associated glycoprotein immunoglobulin M.
Benedetti L; Briani C; Grandis M; Vigo T; Gobbi M; Ghiglione E; Carpo M; Cocito D; Caporale CM; Sormani MP; Mancardi GL; Nobile-Orazio E; Schenone A
J Peripher Nerv Syst; 2007 Jun; 12(2):102-7. PubMed ID: 17565535
[TBL] [Abstract][Full Text] [Related]
27. Differential response to intravenous immunoglobulin (IVIg) therapy among multifocal and polyneuropathy types of painful diabetic neuropathy.
Kawagashira Y; Watanabe H; Morozumi S; Iijima I; Koike H; Hattori N; Sobue G
J Clin Neurosci; 2010 Aug; 17(8):1003-8. PubMed ID: 20627580
[TBL] [Abstract][Full Text] [Related]
28. Comparison between impairment and disability scales in immune-mediated polyneuropathies.
Merkies IS; Schmitz PI; Van Der Meché FG; Van Doorn PA
Muscle Nerve; 2003 Jul; 28(1):93-100. PubMed ID: 12811779
[TBL] [Abstract][Full Text] [Related]
29. Multifocal motor neuropathy: long-term clinical and electrophysiological assessment of intravenous immunoglobulin maintenance treatment.
Van den Berg-Vos RM; Franssen H; Wokke JH; Van den Berg LH
Brain; 2002 Aug; 125(Pt 8):1875-86. PubMed ID: 12135977
[TBL] [Abstract][Full Text] [Related]
30. Neurophysiological and clinical responses to rituximab in patients with anti-MAG polyneuropathy.
Zara G; Zambello R; Ermani M
Clin Neurophysiol; 2011 Dec; 122(12):2518-22. PubMed ID: 21680240
[TBL] [Abstract][Full Text] [Related]
31. Multifocal motor neuropathy: decrease in conduction blocks and reinnervation with long-term IVIg.
Vucic S; Black KR; Chong PS; Cros D
Neurology; 2004 Oct; 63(7):1264-9. PubMed ID: 15477549
[TBL] [Abstract][Full Text] [Related]
32. Short and long-term effect of IVIg in demyelinating neuropathy associated with MGUS, experience of a monocentric study.
Théaudin M; Lozeron P; Lacroix C; Chrétien P; Ducot B; Denier C; Adams D
Rev Neurol (Paris); 2011 Dec; 167(12):897-904. PubMed ID: 22023823
[TBL] [Abstract][Full Text] [Related]
33. An open label clinical trial of complement inhibition in multifocal motor neuropathy.
Fitzpatrick AM; Mann CA; Barry S; Brennan K; Overell JR; Willison HJ
J Peripher Nerv Syst; 2011 Jun; 16(2):84-91. PubMed ID: 21692905
[TBL] [Abstract][Full Text] [Related]
34. A pilot study to compare the use of the Excorim staphylococcal protein immunoadsorption system and IVIG in chronic inflammatory demyelinating polyneuropathy.
Zinman LH; Sutton D; Ng E; Nwe P; Ngo M; Bril V
Transfus Apher Sci; 2005 Nov; 33(3):317-24. PubMed ID: 16239123
[TBL] [Abstract][Full Text] [Related]
35. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura.
Braendstrup P; Bjerrum OW; Nielsen OJ; Jensen BA; Clausen NT; Hansen PB; Andersen I; Schmidt K; Andersen TM; Peterslund NA; Birgens HS; Plesner T; Pedersen BB; Hasselbalch HC
Am J Hematol; 2005 Apr; 78(4):275-80. PubMed ID: 15795920
[TBL] [Abstract][Full Text] [Related]
36. 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease.
Relkin NR; Szabo P; Adamiak B; Burgut T; Monthe C; Lent RW; Younkin S; Younkin L; Schiff R; Weksler ME
Neurobiol Aging; 2009 Nov; 30(11):1728-36. PubMed ID: 18294736
[TBL] [Abstract][Full Text] [Related]
37. Correlates of outcome and response to IVIg in 88 patients with multifocal motor neuropathy.
Karam C
Neurology; 2011 Mar; 76(13):1194; author reply 1194-5. PubMed ID: 21444910
[No Abstract] [Full Text] [Related]
38. Clinical and functional change in multifocal motor neuropathy treated with IVIg.
Chia PK; Hung SKY; Hiew FL
J Clin Neurosci; 2019 Nov; 69():114-119. PubMed ID: 31416736
[TBL] [Abstract][Full Text] [Related]
39. Monitoring the short-term effect of intravenous immunoglobulins in multifocal motor neuropathy using motor unit number index.
Philibert M; Grapperon AM; Delmont E; Attarian S
Clin Neurophysiol; 2017 Jan; 128(1):235-240. PubMed ID: 27988478
[TBL] [Abstract][Full Text] [Related]
40. [The clinical usefulness of high-dose intravenous immunoglobulin therapy for chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy].
Kubori T; Mezaki T; Kaji R; Kimura J; Hamaguchi K; Hirayama K; Kanazawa I; Miyatake T; Mannen T; Kowa H; Yanagisawa N; Goto I; Osame M; Kanda M; Tashiro K; Baba M; Kuroiwa Y; Nagatomo H; Mitsuma T; Shigeta Y; Saida T; Nakajima K; Kawamura J; Murai Y; Kiuchi T
No To Shinkei; 1999 Feb; 51(2):127-35. PubMed ID: 10198901
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
